No connection

Search Results

Analysis Neutral

Supernus finalizes $350M asset acquisition of Navitor’s SPN-820

Apr 08, 2026 05:20 UTC

Supernus finalizes $350M asset acquisition of Navitor’s SPN-820.

  • Supernus Pharmaceuticals (SUPN) has officially entered into anasset purchase agreementwith Navitor Pharmaceuticals, Inc
  • , and Navitor Pharmaceuticals, LLC
  • as of April 1, 2026

Supernus Pharmaceuticals (SUPN) has officially entered into anasset purchase agreementwith Navitor Pharmaceuticals, Inc., and Navitor Pharmaceuticals, LLC. as of April 1, 2026. Supernus may pay up to $350 million in total, triggered by specific development, regulatory, and commercial achievements.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile